Stockreport

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

Biodesix, Inc.  (BDSX) 
PDF Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjus [Read more]